Smoking history as a predictive factor of treatment response in advanced non-small-cell lung cancer: A systematic review

Clinical Lung Cancer

Volumn 13, Issue 4, 2012, Pages 239-251

  Mitchell, Paul ^a   Mok, Tony ^b   Barraclough, Helen ^c   Strizek, Alena ^c   Lew, Rebecca ^d   Van Kooten, Maximiliano ^c  

^a AUSTIN HEALTH   (Australia)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c ELI LILLY AUSTRALIA PTY LTD   (Australia)

^d ProScribe Medical Communications   (Australia)

Author keywords

Antineoplastic agents; Carcinoma; Epidermal growth factor receptor; Non small cell lung cancer; Smoking

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PLACEBO; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE;

CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; ETHNICITY; HUMAN; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SEX DIFFERENCE; SMOKING HABIT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; PROGNOSIS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84861585793     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.08.003     Document Type: Review

References (79)

1. A. Jemal, R. Siegel, E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. D.M. Parkin, F. Bray, J. Ferlay Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108 (Pubitemid 40372904)
3. W.C. Dempke, T. Suto, M. Reck Targeted therapies for non-small cell lung cancer Lung Cancer 67 2010 257 274
4. J.R. Molina, P. Yang, S.D. Cassivi Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship Mayo Clin Proc 83 2008 584 594 (Pubitemid 351720831)
5. R. Feld, S.S. Sridhar, F.A. Shepherd Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review J Thorac Oncol 1 2006 367 376 (Pubitemid 47163993)
6. NSCLC Meta-Analyses Collaborative Group Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials J Clin Oncol 26 2008 4617 4625
7. C.G. Azzoli, S. Baker Jr, S. Temin American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer J Clin Oncol 27 2009 6251 6266
8. G.V. Scagliotti, P. Parikh, J. von Pawel Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
9. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139 (Pubitemid 38637993)
10. J.G. Paez, P.A. Janne, J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500 (Pubitemid 38720929)
11. L.V. Sequist, D.W. Bell, T.J. Lynch Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer J Clin Oncol 25 2007 587 595 (Pubitemid 350002967)
12. R. Rosell, T. Moran, C. Queralt Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 2009 958 967
13. H. Shigematsu, L. Lin, T. Takahashi Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 2005 339 346 (Pubitemid 40425952)
14. A. Chang, P. Parikh, S. Thongprasert Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study J Thorac Oncol 1 2006 847 855 (Pubitemid 47181391)
15. E.S. Kim, V. Hirsh, T. Mok Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet 372 2008 1809 1818
16. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132 (Pubitemid 41058344)
17. N. Thatcher, A. Chang, P. Parikh Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537 (Pubitemid 41540110)
18. J.M. Samet, E. Avila-Tang, P. Boffetta Lung cancer in never smokers: clinical epidemiology and environmental risk factors Clin Cancer Res 15 2009 5626 5645
19. G.V. Scagliotti, M. Longo, S. Novello Nonsmall cell lung cancer in never smokers Curr Opin Oncol 21 2009 99 104
20. S. Sun, J.H. Schiller, A.F. Gazdar Lung cancer in never smokers - a different disease Nat Rev Cancer 7 2007 778 790 (Pubitemid 47463669)
21. World Health Organization WHO Report on the Global Tobacco Epidemic, 2008: The MPOWER Package Geneva, Switzerland: 2008 http://www.who.int/tobacco/ mpower/2008/en/index.html Accessed: October 29, 2010
22. M.J. Thun, L.M. Hannan, L.L. Adams-Campbell Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies PLoS Med 5 2008 e185
23. J. Subramanian, R. Govindan Lung cancer in never smokers: a review J Clin Oncol 25 2007 561 570 (Pubitemid 350002964)
24. C.M. Rudin, E. Avila-Tang, C.C. Harris Lung cancer in never smokers: molecular profiles and therapeutic implications Clin Cancer Res 15 2009 5646 5661
25. T. Yano, N. Miura, T. Takenaka Never-smoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival Cancer 113 2008 1012 1018
26. W. Pao, V. Miller, M. Zakowski EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 101 2004 13306 13311 (Pubitemid 39209661)
27. D.A. Eberhard, B.E. Johnson, L.C. Amler Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 2005 5900 5909
28. T. Itaya, N. Yamaoto, M. Ando Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer Cancer Sci 98 2007 226 230 (Pubitemid 44941875)
29. Y.Y. Janjigian, K. McDonnell, M.G. Kris Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer Cancer 116 2010 670 675
30. T. Kawaguchi, M. Takada, A. Kubo Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC J Thorac Oncol 5 2010 620 630
31. F. Cappuzzo, T. Ciuleanu, L. Stelmakh Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 2010 521 529
32. G.M. Clark Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib Mol Oncol 1 2008 406 412
33. G.M. Clark, D.M. Zborowski, P. Santabarbara Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21 Clin Lung Cancer 7 2006 389 394 (Pubitemid 44043548)
34. G.D. Goss, A. Arnold, F.A. Shepherd Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 Study J Clin Oncol 28 2010 49 55
35. C. Gridelli, F. Ciardiello, R. Feld International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial J Clin Oncol 28 suppl 2010 abstract 7508 www.asco.org Accessed: September 4, 2011
36. K. Kubota, M. Kawahara, M. Ogawara Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study Lancet Oncol 9 2008 1135 1142
37. R. Maruyama, Y. Nishiwaki, T. Tamura Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer J Clin Oncol 26 2008 4244 4252
38. T.S. Mok, Y.L. Wu, S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
39. R. Pirker, J.R. Pereira, A. Szczesna Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 2009 1525 1531
40. K.N. Syrigos, J. Vansteenkiste, P. Parikh Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer Ann Oncol 21 2010 556 561
41. R. Lilenbaum, R. Axelrod, S. Thomas Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 J Clin Oncol 26 2008 863 869 (Pubitemid 351398077)
42. N. Mylonakis, N. Tsavaris, C. Bacoyiannis A randomized prospective study of cisplatin and vinblastine versus cisplatin, vinblastine and mitomycin in advanced non-small cell lung cancer Ann Oncol 3 1992 127 130
43. T. Mitsudomi, S. Morita, Y. Yatabe Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
44. U. Gatzemeier, A. Pluzanska, A. Szczesna Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 2007 1545 1552 (Pubitemid 46733081)
45. R.S. Herbst, D. Prager, R. Hermann TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
46. T.J. Lynch, T. Patel, L. Dreisbach Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099 J Clin Oncol 28 2010 911 917
47. T.S. Mok, Y.L. Wu, C.J. Yu Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer J Clin Oncol 27 2009 5080 5087
48. R. Pirker, J. Rodrigues-Pereira, A. Szczesna Prognostic factors in advanced NSCLC: experience from the FLEX trial J Clin Oncol 27 suppl 2009 abstract 8083 http://www.asco.org Accessed: September 4, 2011
49. K. Takeda, T. Hida, T. Sato Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a West Japan Thoracic Oncology Group trial (WJTOG0203) J Clin Oncol 28 2010 753 760
50. J.V. Heymach, L. Paz-Ares, F. De Braud Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer J Clin Oncol 26 2008 5407 5415
51. M. Reck, J. von Pawel, P. Zatloukal Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL J Clin Oncol 27 2009 1227 1234
52. G. Scagliotti, S. Novello, J. von Pawel Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer J Clin Oncol 28 2010 1835 1842
53. O. Arrieta, C.H. González-De la Rosa, E. Aréchaga-Ocampo Randomized phase II trial of all-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer J Clin Oncol 28 2010 3463 3471
54. R. Ramlau, P. Zatloukal, J. Jassem Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I J Clin Oncol 26 2008 1886 1892
55. G.R. Blumenschein, F.R. Khuri, J. von Pawel Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II J Clin Oncol 26 2008 1879 1885
56. D.D. Karp, L.G. Paz-Ares, S. Novello Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer J Clin Oncol 27 2009 2516 2522
57. R.S. Herbst, Y. Sun, W.E.E. Eberhardt Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial Lancet Oncol 11 2010 619 626
58. B. Nguyen, S. Paul, K. Posther The effect of smoking history on survival outcome: an exploratory analysis of a phase III study of gemcitabine and cisplatin in patients with advanced non-small cell lung cancer (NSCLC) J Clin Oncol 24 suppl 2006 abstract 7141 http://www.asco.org Accessed: September 4, 2011
59. G.V. Scagliotti, F. De Marinis, M. Rinaldi The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial J Thorac Oncol 4 2009 1568 1571
60. C.H. Yang, L. Simms, K. Park Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a Phase III trial J Thorac Oncol 5 2010 688 695
61. S. Teramukai, T. Nishimura, M. Nakagawa Predictors and impacts of second-line chemotherapy on survival after progression in patients with advanced non-small cell lung cancer (NSCLC) J Clin Oncol 25 suppl 2007 abstract 7675 http://www.asco.org Accessed: September 4, 2011
62. G. Giaccone, R.S. Herbst, C. Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1 J Clin Oncol 22 2004 777 784 (Pubitemid 41103588)
63. R.S. Herbst, G. Giaccone, J.H. Schiller Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2 J Clin Oncol 22 2004 785 794 (Pubitemid 41103589)
64. M.C. Garassino, K. Borgonovo, A. Rossi Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis Anticancer Res 29 2009 2691 2701
65. M. Maemondo, A. Inoue, K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
66. J. Li, M. Zhao, P. He Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes Clin Cancer Res 13 2007 3731 3737 (Pubitemid 46955138)
67. M. Hamilton, J.L. Wolf, J. Rusk Effects of smoking on the pharmacokinetics of erlotinib Clin Cancer Res 12 2006 2166 2171
68. A.N. Hughes, M.E. O'Brien, W.J. Petty Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers J Clin Oncol 27 2009 1220 1226
69. L.L. Waller, A.A. Miller, N.P. Streer Overcoming pharmacokinetic resistance to erlotinib: rationale and preliminary findings from a phase II study J Thorac Oncol 5 2010 S247
70. National Health Interview Survey Adult tobacco use information - Glossary [Centers for Disease Control and Prevention website] www.cdc.gov/nchs/nhis/ tobacco/tobacco-glossary.htm 2009 Accessed: November 5, 2010
71. E.R. Gritz, C. Dresler, L. Sarna Smoking, the missing drug interaction in clinical trials: ignoring the obvious Cancer Epidemiol Biomarkers Prev 14 2005 2287 2293 (Pubitemid 41437826)
72. S.S. Coughlin Recall bias in epidemiologic studies J Clin Epidemiol 43 1990 87 91 (Pubitemid 20036970)
73. T. Kawaguchi, M. Takada, A. Kubo Gender, histology, and time of diagnosis are important factors for prognosis: analysis of 1499 never-smokers with advanced non-small cell lung cancer in Japan J Thorac Oncol 5 2010 1011 1017
74. R.A. Meguid, C.M. Hooker, J. Harris Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers Chest 138 2010 500 509
75. L.T. Nordquist, G.R. Simon, A. Cantor Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung Chest 126 2004 347 351 (Pubitemid 39093415)
76. C.M. Tammemagi, C. Neslund-Dudas, M. Simoff Smoking and lung cancer survival: the role of comorbidity and treatment Chest 125 2004 27 37 (Pubitemid 38114560)
77. C.K. Toh, E.H. Wong, W.T. Lim The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis Chest 126 2004 1750 1756
78. K.S. Ogle, G.M. Swanson, N. Woods Cancer and comorbidity: redefining chronic diseases Cancer 88 2000 653 663 (Pubitemid 30056943)
79. Y.J. Lee, H.S. Shim, Y.A. Kang Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer J Cancer Res Clin Oncol 136 2010 1937 1944